| Outcome Measures: |
Primary: Area under the curve (AUCins(0-1h)), Area under the human insulin serum concentration - time curve from t=0 to 1 hour, 1 hour | Secondary: Pharmacokinetics: Early t0.5max ins/lisp, Time to first observed half maximum serum human insulin / insulin lispro concentration, up to 10 hours post administration|Glucodynamics: Area under the glucose infusion rate - time curve from t=0 to 10 hours, Area under the glucose infusion rate - time curve from t=0 to 10 hours, 10 hours|Glucodynamics: Early t0.5 Glucose Infusion Rate max (GIRmax), Time to first observed half maximum glucose infusion rate, 10 hours|Glucodynamics: GIRmax - Maximum glucose infusion rate, Maximum glucose infusion rate, 10 hours|Pharmacokinetics: AUCins/lisp(0-10h): Area under the human insulin / insulin lispro serum concentration, Area under the human insulin / insulin lispro serum concentration - Time curve from t=0 to 10 hours, 10 hours|Pharmacokinetics: Tmax(ins/lisp) - Time to maximum observed serum human insulin concentration and insulin lispro concentration, Time to maximum observed serum human insulin concentration and insulin lispro concentration, 10 hours|Safety and tolerability: adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters, Adverse events, local tolerability, vital signs variation, ECG, laboratory safety parameters, up to 7 weeks|Pharmacokinetics: Cmax(ins/lisp), Maximum observed human insulin / insulin lispro serum concentration, up to 10 hours|Glucodynamics: Area under the glucose infusion rate - time curve from t=0 to 2 hours, Area under the glucose infusion rate - time curve from t=0 to 2 hours, 2 hours post administration
|
